The Complete Guide to Weight Loss Treatment in the UK (2026): GLP 1, How It Works, Costs & What to Expect

The most clinically effective prescription weight loss treatments currently available in the UK are GLP 1 receptor agonists, a class of medicines that work by regulating appetite, slowing digestion, and influencing the brain's satiety signals. The three principal options available privately are Mounjaro (tirzepatide), Wegovy (semaglutide), and Saxenda (liraglutide).

Based on clinical trial data:

• Mounjaro produces average weight loss of 15 to 20% of body weight, based on SURMOUNT trials.
• Wegovy produces average weight loss of 12 to 15% of body weight, based on STEP trials.
• Saxenda produces average weight loss of 5 to 8% of body weight, based on SCALE trials.

Both Mounjaro and Wegovy are NICE approved and available through NHS specialist services for eligible patients. All three are available privately through GPhC registered UK pharmacies following a clinical assessment.

This guide covers everything you need to understand about weight loss treatment in the UK: what these medications are, how they work, who is eligible, what they cost, how to access them safely, and what to realistically expect from treatment.

What Is GLP 1?

GLP 1 stands for glucagon like peptide 1, a hormone produced naturally in the gut in response to eating. When you consume food, your intestinal cells release GLP 1, which performs several functions simultaneously.

• It signals the pancreas to release insulin, lowering blood glucose.
• It suppresses glucagon production, reducing glucose release from the liver.
• It slows gastric emptying, so food leaves the stomach more slowly and produces sustained fullness.
• It signals the hypothalamus in the brain to reduce appetite and increase satiety.

In people with obesity or excess weight, this natural GLP 1 signalling system is often dysregulated, meaning the body does not receive or respond to these satiety and appetite signals as effectively as it should. GLP 1 receptor agonists are designed to mimic and amplify this system, producing stronger and more sustained appetite regulation than the body achieves naturally.

How GLP 1 Receptor Agonists Work for Weight Loss

When a GLP 1 medication is used, it binds to GLP 1 receptors throughout the body, including in the pancreas, gut, and brain. It activates the same pathways as natural GLP 1, but with significantly greater potency and duration.

The result is a combination of effects that work together to reduce food intake and support weight loss.

• Reduced appetite: the hypothalamus receives stronger satiety signals, meaning the desire to eat is suppressed between meals and portion sizes naturally decrease.
• Slower gastric emptying: food stays in the stomach longer, sustaining the physical sensation of fullness and reducing the speed at which hunger returns after eating.
• Reduced food reward signalling: GLP 1 receptors in the brain's reward centres, including the nucleus accumbens, are also activated, reducing the psychological drive toward high calorie, high reward foods.
• Improved blood glucose regulation: insulin is released more effectively in response to food, and glucose production between meals is reduced. This is particularly relevant for patients with type 2 diabetes or prediabetes.

These mechanisms do not require dietary restriction to activate, but clinical evidence consistently shows that they work most effectively when combined with lifestyle changes. GLP 1 treatment is not a replacement for a sustainable diet and activity approach. It is a pharmacological tool that makes those approaches more achievable for people whose biology works against them.

The Difference Between GLP 1 and GIP plus GLP 1

Mounjaro (tirzepatide) differs from Wegovy and Saxenda in one clinically significant way: it acts on two receptors simultaneously.

In addition to the GLP 1 receptor, tirzepatide also activates the GIP (glucose dependent insulinotropic polypeptide) receptor. GIP is another gut hormone involved in energy metabolism and fat storage. By activating both pathways together, Mounjaro produces a synergistic effect that exceeds the appetite and weight loss response seen with GLP 1 alone, which is reflected in the higher average weight loss benchmarks from the SURMOUNT trials compared to the STEP (Wegovy) and SCALE (Saxenda) data.

This dual mechanism is why Mounjaro is considered a next generation GLP 1 treatment. It operates on the same fundamental biological system but with an additional receptor target that enhances the overall effect.

Mounjaro (Tirzepatide)

Mounjaro is the most recently approved and highest efficacy GLP 1 option currently available in the UK. The SURMOUNT 1 trial demonstrated average weight loss of 20.9% in participants without diabetes who reached the 15 mg maintenance dose, a result that significantly exceeded what had been seen with any previous pharmacological weight management intervention.

The KwikPen delivery device delivers a fixed 0.6 mL dose per weekly treatment, with four doses per pen. The titration protocol runs from 2.5 mg to 15 mg across six dose steps, each held for a minimum of four weeks before escalation.

For deeper clinical context, read our full Mounjaro tirzepatide guide. For current provider pricing, the Mounjaro price comparison page gives a focused view across UK pharmacies.

Wegovy (Semaglutide)

Wegovy is the established weekly semaglutide treatment for weight management, distinct from Ozempic (semaglutide 1 mg), which is approved for type 2 diabetes management but not licensed for weight management in the UK. The STEP trials demonstrated average weight loss of 14.9% over 68 weeks at the 2.4 mg maintenance dose, with a significant proportion of participants achieving 15% or more.

Wegovy uses a single use auto injector pen. There is no dial or click mechanism. Each pen delivers one dose, making it simpler in operation than the multi dose Mounjaro KwikPen.

For a complete clinical overview, see the Wegovy weight loss guide.

Saxenda (Liraglutide)

Saxenda is the original GLP 1 weight loss treatment and has the longest clinical track record of the three. It was approved in the UK before Wegovy and Mounjaro and remains an established option, particularly for patients whose prescribers prefer a more conservative starting point or for whom daily dosing is clinically preferable.

The lower average weight loss benchmark relative to the newer weekly options reflects both the older generation of the compound and the single receptor mechanism. However, individual responses vary, and some patients achieve significant outcomes on liraglutide.

For a complete clinical guide, see the Saxenda weight loss treatment guide.

NHS Eligibility Criteria

For NHS access to Mounjaro or Wegovy through specialist weight management services, NICE guidance sets the following general criteria.

The practical gap: NICE approval does not mean universal NHS availability. Local commissioning groups implement the guidance at different speeds and with different criteria. Many patients who qualify under NICE thresholds find that NHS access in their area is limited or has significant waiting times, which is the primary reason most UK patients continue to access these treatments privately in 2026.

Private Eligibility Criteria

Private prescribers generally follow similar BMI thresholds to NHS guidance, though the specific criteria can vary by provider.

• BMI 30 or above: typically eligible for private GLP 1 prescribing without additional conditions.
• BMI 27 to 29.9: may be eligible with at least one qualifying weight related health condition.
• BMI below 27: prescription GLP 1 treatment is not typically appropriate; lifestyle and non pharmacological approaches are usually recommended first.

A licensed prescriber makes the final eligibility determination following a full clinical assessment, which includes reviewing medical history, current medications, and any contraindications, not just calculating BMI.

To understand your BMI category and its implications for treatment eligibility, the BMI calculator with NHS eligibility context provides an NHS aligned result in any UK measurement format.

Who Should Not Use GLP 1 Treatments

GLP 1 medications are not appropriate for everyone. Common contraindications include:

• Personal or family history of medullary thyroid carcinoma (MTC).
• Multiple endocrine neoplasia syndrome type 2 (MEN 2).
• Severe gastrointestinal conditions, for example gastroparesis.
• Pregnancy or breastfeeding.
• Certain concurrent medications that interact with GLP 1 drugs.
• Severe kidney or liver impairment, assessed case by case.

A thorough clinical assessment by a licensed prescriber is essential, not optional, before starting any of these treatments.

Route 1: NHS (Specialist Weight Management Service)

The NHS route for GLP 1 treatment involves:

1. GP consultation: discuss weight management and request referral.
2. Referral to Tier 3 weight management service: specialist multidisciplinary service.
3. Assessment: BMI, comorbidities, previous weight management attempts, clinical suitability.
4. Prescription initiation: if eligible, treatment begins under specialist supervision.
5. Ongoing monitoring: regular review by the specialist team.

Advantages: no medication cost to the patient, although standard NHS prescription charge applies where relevant.

Disadvantages: availability varies significantly by region, waiting times can be lengthy, and eligibility criteria may be applied more strictly than the minimum NICE thresholds.

Route 2: Private Online Pharmacy (Most Common Route in 2026)

The private online route involves:

1. Research and comparison: understanding options, comparing providers and prices.
2. Online clinical assessment: questionnaire based assessment reviewed by a licensed prescriber.
3. Prescription issued: if clinically suitable, the prescriber issues a private prescription.
4. Medication dispensed: GPhC registered pharmacy fulfils and delivers the prescription.
5. Ongoing renewal: periodic prescription renewal reviews, with frequency varying by provider.

Advantages: no waiting list, accessible without GP involvement, and competitive pricing across multiple providers.

Disadvantages: cost, variable quality of clinical assessment process, need for careful pharmacy verification, and less clinical oversight than the NHS specialist route.

Route 3: Private Clinic

Some patients access GLP 1 treatment through private weight management clinics, either face to face or via telehealth, which typically offer more comprehensive clinical assessment and monitoring than standard online pharmacy pathways.

Advantages: higher quality clinical oversight, in person assessment available, and better access to a prescriber if complications arise.

Disadvantages: higher cost than the online pharmacy route, and not all clinics cover all treatments.

Private Market Pricing Overview (2026)

All three treatments follow a titration pricing structure. Costs increase with each dose step.

Prices are approximate, based on independent monitoring of GPhC registered UK pharmacies in 2026.

Additional Costs to Factor In

Beyond the pen price, the following components commonly affect total monthly spend:

• Consultation fees: £0 to £50 per prescription cycle, varying by provider.
• Delivery: £0 to £15 per order, because cold chain handling is required.
• Programme or monitoring fees: £0 to £40 per month where applicable.
• Needles and consumables: variable, depending on provider package.

For the most complete and current provider by provider price comparison, including Trustpilot ratings and GPhC verification status, see the Mounjaro vs Wegovy vs Saxenda price comparison.

For verified lowest cost options across all three treatments, see the cheapest weight loss treatment options UK hub.

Timeline: When Does Weight Loss Begin?

Most patients on GLP 1 treatment notice appetite changes within the first two to four weeks. The biological mechanisms are active from the first dose. Visible weight loss typically begins during the first month, though the rate of loss varies significantly by individual.

A general timeline:

Side Effects: What Is Normal?

The most common side effects of GLP 1 treatment are gastrointestinal and are most pronounced during the first weeks of treatment and at each dose increase:

• Nausea: the most commonly reported side effect; typically reduces after the first 2 to 4 weeks at each dose step.
• Vomiting: less common than nausea; usually occurs if eating too quickly or in excessive amounts.
• Diarrhoea or constipation: one or the other is commonly reported; typically resolves as the body adjusts.
• Reduced appetite: technically the intended mechanism, not a side effect, but it can feel dramatic initially.
• Fatigue: reported by some patients, particularly in early weeks.

Less common but more serious side effects that require medical review:

• Severe persistent nausea or vomiting.
• Signs of pancreatitis, including severe abdominal pain.
• Gallbladder issues.
• Rapid heart rate.
• Injection site reactions that do not resolve.

Always report any concerning symptoms to your prescriber promptly.

The Role of Lifestyle: Why Treatment Works Best With It

GLP 1 medications are not a standalone solution. Clinical trial data consistently shows better outcomes when treatment is combined with meaningful lifestyle changes, and the biological mechanisms of GLP 1 drugs actually make lifestyle changes more achievable.

• Diet: appetite suppression from GLP 1 treatment makes reducing calorie intake significantly easier. Most patients naturally reduce portion sizes and find high calorie foods less appealing. Prioritising protein and vegetables, and reducing ultra processed food intake, supports better outcomes.
• Exercise: GLP 1 medications do not selectively preserve muscle mass during weight loss. This requires deliberate effort. Resistance training during treatment helps ensure that weight loss comes from fat tissue rather than muscle, which matters for long term metabolic health.
• Sleep: poor sleep quality affects cortisol and ghrelin levels, both of which influence appetite and weight. Addressing sleep quality alongside GLP 1 treatment supports better outcomes.
• Stress management: chronic stress elevates cortisol, which promotes fat storage particularly around the abdomen. Managing psychological stress is a relevant component of a holistic weight management approach.

The GPhC Verification Checklist

Every GPhC registered pharmacy in the UK has a public registration number verifiable at pharmacyregulation.org. This is the minimum baseline for any online pharmacy dispensing prescription medicines. Before using any provider:

1. Verify GPhC registration at pharmacyregulation.org.
2. Check the MHRA internet pharmacy logo, making sure it is displayed and linked on the homepage.
3. Confirm that a named GMC registered prescriber is identified.
4. Verify the Trustpilot rating independently at trustpilot.com.
5. Confirm full cost disclosure before checkout, including all visible fees.
6. Check that delivery confirms cold chain handling.

Red Flags to Avoid

• No GPhC registration number visible.
• No named prescriber on the clinical team.
• Clinical "assessment" is purely a questionnaire with no human review.
• Prices significantly below market range with no explanation.
• No cold chain delivery confirmation.
• No mechanism for contacting a prescriber after purchase.

Notifying Your GP

Whether you access treatment privately or through NHS, it is good practice to inform your GP that you are taking a GLP 1 medication. This ensures your medical records are complete, avoids potential drug interactions with any other medications your GP prescribes, and allows your GP to monitor relevant health markers such as blood glucose, blood pressure, and kidney function as part of routine care.

Weight loss treatment in the UK in 2026 is more clinically effective, more accessible, and better evidenced than at any previous point. The GLP 1 class of medications, particularly Mounjaro and Wegovy, represents a genuine advance in pharmacological weight management, producing outcomes that were not achievable with older treatment options.

However, accessing treatment well requires understanding:

• What these medications are and how they work: not just what they cost.
• Whether you are clinically eligible: BMI, comorbidities, and contraindications.
• Which route is appropriate: NHS, private online pharmacy, or private clinic.
• What the realistic total cost is: across the full titration schedule, not just the starter price.
• How to choose a safe, legitimate provider: GPhC verification, Trustpilot, and prescriber credentials.
• What to expect from treatment: timeline, side effects, lifestyle integration, and long term maintenance.

This guide has covered all of those dimensions. For the next steps in your research, compare current prices across all three treatments through the Healthwise360 comparison hub, calculate your BMI with the BMI calculator with eligibility context, or read the full treatment guide most relevant to you: Mounjaro, Wegovy, or Saxenda.